For treatment of HR+, HER2- recurrent or metastatic breast cancer (MBC) in postmenopausal women or premenopausal women receiving ovarian ablation or suppression
National Comprehensive Cancer Network® (NCCN®) recommends abemaciclib (Verzenio®) as a treatment option in combination with fulvestrant or an AI and as a single agent1
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer V.1.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed January 15, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org/patients.